Freshleaf Analytics Q1 2019

FreshLeaf Analytics Q1 2019

Our Q1 2019 report gives insight for the first time into new metrics around product floor prices, revenue forecasts and market size.

We have found that pricing competition continues to intensify as new products enter the market, with Australian doctors now having a choice of over 50 products to prescribe from.

Patient dosages have increased as the market matures and more patients find their ‘optimal’ dose requirements, and this has led to a slight increase in average monthly costs for patients. We expect around 15,000 – 20,000 new patients to enter the market this year, with monthly product revenues to approach A$3.6M by the end of 2019.

We expect around 15,000 – 20,000 new patients to enter the market this year, with monthly product revenues to approach A$3.6M by the end of 2019.

Download our reports